Join our daily newsletter At The Bell to receive exclusive market insights
- PharmAust (PAA) signs agreements to expand its canine lymphoma studies into New Zealand
- A deal has been penned with Veterinary Specialists Auckland and Intuit Regulatory to expand PharmAust’s Phase 2b lymphoma studies, in preparation for a Phase 3 trial
- The trial will test the hypothesis that monepantel will provide a well-tolerated oral therapy for canines with lymphoma
- Phase 3 trials are due to begin in May 2022
- PharmAust is down 12.5 per cent to $0.10 per share at 10:42 am AEDT
PharmAust (PAA) has signed agreements to expand its canine lymphoma studies into New Zealand.
The clinical-stage biotech company has penned a deal with Veterinary Specialists Auckland and Intuit Regulatory to expand its Phase 2b lymphoma studies, in preparation for its Phase 3 trial.
The trial will test the hypothesis that monepantel will provide a well-tolerated oral therapy for canines with lymphoma.
Monepantel is PharmAust’s lead drug candidate, which has been shown to have key influences in cancer growth and neurodegenerative diseases. If successful, the treatment would be superior to steroids alone and without the costs and risks of chemotherapy.
As part of the deal, PharmAust has signed an agreement with Dr Mike Coleman and Dr Tommy Fluen, fellows of the Australian and New Zealand College of Veterinary Scientists and registered specialists in small animal internal medicine.
Regulatory and ethical compliance will be overseen by Dr Julia McNab of Intuit Regulatory who has specialist expertise in Phase 3 design and registration.
“Establishing trial procedures, structures and systems with these groups and receiving their feedback will provide great value to PharmAust in preparing for Phase 3 and potentially later with product roll-out,” said PharmAust’s Chief Scientific Officer, Dr Richard Mollard.
The Phase 3 trials are due to begin in May 2022.
PharmAust is down 12.5 per cent to $0.10 per share at 10:42 am AEDT.
